Citius Pharmaceuticals Stock Analysis
| CTXR Stock | USD 1.01 0.02 1.94% |
Citius Pharmaceuticals is undervalued with Real Value of 1.91 and Hype Value of 0.97. The main objective of Citius Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Citius Pharmaceuticals is worth, separate from its market price. There are two main types of Citius Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Citius Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Citius Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Citius Stock trading window is adjusted to America/New York timezone.
Citius |
Citius Stock Analysis Notes
The company has price-to-book (P/B) ratio of 0.14. Some equities with similar Price to Book (P/B) outperform the market in the long run. Citius Pharmaceuticals recorded a loss per share of 5.82. The entity last dividend was issued on the 9th of June 2017. The firm had 1:25 split on the 26th of November 2024. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Citius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people. For more info on Citius Pharmaceuticals please contact Myron Holubiak at 908 967 6677 or go to https://citiuspharma.com.Citius Pharmaceuticals Investment Alerts
| Citius Pharmaceuticals generated a negative expected return over the last 90 days | |
| Citius Pharmaceuticals has high historical volatility and very poor performance | |
| Citius Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (39.43 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Citius Pharmaceuticals currently holds about 48.04 M in cash with (28.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Citius Pharmaceuticals has a very weak financial position based on the latest SEC disclosures |
Citius Pharmaceuticals Upcoming and Recent Events
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of January 2025 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Citius Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.85 M.Technical Drivers
As of the 5th of April, Citius Pharmaceuticals shows the Standard Deviation of 6.04, risk adjusted performance of (0.38), and Mean Deviation of 4.15. Citius Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Citius Pharmaceuticals market risk adjusted performance and treynor ratio to decide if Citius Pharmaceuticals is priced correctly, providing market reflects its regular price of 1.01 per share. Given that Citius Pharmaceuticals is a hitting penny stock territory we recommend to closely look at its jensen alpha.Citius Pharmaceuticals Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Citius Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Citius Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Citius Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Citius Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Citius Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Citius Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Citius Pharmaceuticals Outstanding Bonds
Citius Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Citius Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Citius bonds can be classified according to their maturity, which is the date when Citius Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| C 3057 25 JAN 33 Corp BondUS17327CAQ69 | View | |
| CITIGROUP INC Corp BondUS17327CAM55 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| US17328WP446 Corp BondUS17328WP446 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Citius Pharmaceuticals Predictive Daily Indicators
Citius Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Citius Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Citius Pharmaceuticals Forecast Models
Citius Pharmaceuticals' time-series forecasting models are one of many Citius Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Citius Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Citius Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Citius Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Citius shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Citius Pharmaceuticals. By using and applying Citius Stock analysis, traders can create a robust methodology for identifying Citius entry and exit points for their positions.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Citius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Citius Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.